We are live on ! Find out more
LIMN

Liminatus Pharma
LIMN

11 hedge funds and large institutions have $193K invested in Liminatus Pharma in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

10% more funds holding

Funds holding: 10 → 11 (+1)

0.17% more ownership

Funds ownership: 1.01% → 1.17% (+0.17%)

56% less capital invested

Capital invested by funds: $437K → $193K (-$244K)

Holders
11
Holders Change
+1
Holders Change %
+10%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$78.8K
2
Two Sigma Investments
Two Sigma Investments
New York
+$39.2K
3
TSS
Two Sigma Securities
New York
+$13.2K
4
TRCT
Tower Research Capital (TRC)
New York
+$7.83K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.44K

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$66.2K
2
UBS Group
UBS Group
Switzerland
-$23.5K
3
Squarepoint
Squarepoint
New York
-$17.4K

LIMN Hedge Fund Activity: Q4 2025 in Review

11 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in Liminatus Pharma (LIMN) for Q4 2025, worth a combined $193K — down 56% from $437K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new LIMN positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $78.8K. The largest seller was Jane Street, exiting entirely with an estimated $66.2K sold.

  • 11 institutional investors held Liminatus Pharma (LIMN) as of Q4 2025, up from 10 in Q3 2025.
  • Funds reported $193K of Liminatus Pharma stock for Q4 2025, down 56% quarter-over-quarter.
  • 3 funds opened new Liminatus Pharma positions in Q4 2025 and 2 closed out, a net change of +1 holder.
  • The largest Liminatus Pharma buyer in Q4 2025 was Citadel Advisors, an estimated $78.8K added.
  • The largest Liminatus Pharma seller in Q4 2025 was Jane Street, an estimated $66.2K sold.

Based on aggregated 13F filings for Q4 2025.